Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 1, 2011, Pages 278-285

  Zhang, Yu ^a   Zhang, Jingfa ^b,c   Wang, Qingping ^a   Lei, Xia ^c   Chu, Qing ^c   Xu, Guo Tong ^b,c   Ye, Wen ^a,b  

^a FUDAN UNIVERSITY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EXCITATORY AMINO ACID TRANSPORTER 4; EXENDIN 4 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLUTAMIC ACID; MESSENGER RNA; UNCLASSIFIED DRUG; EXCITATORY AMINO ACID TRANSPORTER 1; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE RECEPTOR; PEPTIDE; SLC1A3 PROTEIN, RAT; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B WAVE; CELL COUNT; CELL PROTECTION; CONTROLLED STUDY; CULTURE MEDIUM; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; ELECTRORETINOGRAPHY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MUELLER CELL; NONHUMAN; OSCILLATORY POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA BIPOLAR GANGLION CELL; RETINA CELL; RETINA THICKNESS; STREPTOZOCIN DIABETES; VISUAL SYSTEM PARAMETERS; ANIMAL; CELL CULTURE; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; FLUORESCENCE MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; RETINA; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CELL COUNT; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; ELECTRORETINOGRAPHY; EXCITATORY AMINO ACID TRANSPORTER 1; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLUCAGON-LIKE PEPTIDE 1; GLUTAMIC ACID; HYPOGLYCEMIC AGENTS; INTRAVITREAL INJECTIONS; MALE; MICROSCOPY, FLUORESCENCE; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; RETINA; RNA, MESSENGER; VENOMS;

EID: 79952230999     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4727     Document Type: Article

References (53)

1. National Society to Prevent Blindness. Vision Problems in the U.S.: Facts and Figures. Schaumburg, IL: Prevent Blindness America; 1980.
2. Saaddine JBH, Narayan AA, Venkat Zhang KM, Klein X, Boyle R, James P. Projection of diabetic retinopathy and other major eye diseases among people with diabetes mellitus: United States: 2005-2050. Arch Ophthalmol. 2008;126:1740-1747.
3. Abu-El-Asrar AM, Dralands L, Missotten L, et al. Expression of apoptosis markers in the retinas of human subjects with diabetes. Invest Ophthalmol Vis Sci. 2004;45:2760-2766.
4. Lieth E, Gardner TW, Barber AJ, et al. Retinal neurodegeneration: early pathology in diabetes. Clin Exp Ophthalmol. 2000;28:3-8.
5. Gardner TW, Antonetti DA, Barber AJ, LaNoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv Ophthalmol. 2002;47(suppl 2):S253-S262.
6. Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008;49:732-742.
7. Doyle ME, Egan JM. Glucagon-like peptide-1. Recent Prog Horm Res. 2001;56:377-400.
8. Xu GK, Laybutt H, Duvivier-Kali DR, et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes. 2007;56:1551-1558.
9. Malendowicz LKM, Nussdorfer C, Nowak GG, Zyterska KW, Ziolkowska A. Effects of prolonged exendin-4 administration on entero-insular axis of normal and streptozotocin-induced diabetic rats. Int J Mol Med. 2003;11:763-766.
10. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycemia by exogenous glucagonlike peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993;36:741-744.
11. Abraham EJL, Lin CA, Zulewski JC, Habener JF. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology. 2002;143:3152-3161.
12. Buteau JR, Susini R, Prentki SM. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia. 1999;42:856-864.
13. Bose AKM, Carr MM, Brand RD, Yellon CL, Derek M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes. 2005;54:146-151.
14. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev. 1999;20:876-913.
15. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology. 2001;142:521-527.
16. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002;18:430-441.
17. List JF, He H, Habener JF. Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin. Regul Peptides. 2006;134: 149-157.
18. Schlatter CB, Drewe JP, Gutmann H. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Peptides. 2007;141:120-128.
19. Gershengorn MCH, Wei AA, Geras-Raaka C, Marcus-Samuels E, Raaka B, Bruce M. Epithelial-to-mesenchymal transition generates proliferative human islet precursor cells. Science. 2004;306:2261-2264.
20. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci. 1995;7:2294-2300.
21. Satoh FB, Small SA, Falzon CJ, et al. Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocrinology. 2000;141:1301-1309.
22. During MJC, Zuzga L, Francis DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173-1179.
23. Perry T, Lahiri DK, Chen D, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factormediated differentiation in PC12 cells. J Pharmacol Exp Ther. 2002;300:958-966.
24. Goke R, Fehmann HC, Linn T, et al. Exendin-4 is a high potency agonist and truncated exendin-(9 -39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting cells. J Biol Chem. 1993;268:19650-19655.
25. Guerci B, Martin CS. Exenatide: its position in the treatment of type 2 diabetes. Ann Endocrinol (Paris). 2008;69:201-209.
26. Lupi RM, Del Guerra R, Bugliani S, et al. Effects of exendin-4 on islets from type 2 diabetes patients. Diabetes Obes Metab. 2008; 10:515-519.
27. Zhang Y, Wang O, Zhang J, Lei X, Xu GT, Ye W. Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247:699-706.
28. Ehinger B. Glial and neuronal uptake of GABA, glutamic acid, glutamine and glutathione in the rabbit retina. Exp Eye Res. 1977; 25:221-234.
29. Brandon C, Lam DM-K. L-glutamic acid: a neurotransmitter candidate for cone photoreceptors in human and rat retinas. Proc Natl Acad Sci U S A. 1983;80:5117-5121.
30. Fletcher EL, Kalloniatis M. Localisation of amino acid neurotransmitters during postnatal development of the rat retina. J Comp Neurol. 1997;380:449-471.
31. Marmor MF, Holder GE, Seeliger MW, Yamamoto S. Standard for clinical electroretinography (2004 update). Doc Ophthalmol. 2004;108:107-114.
32. Tzekov R, Arden GB. The electroretinogram in diabetic retinopathy. Surv Ophthalmol. 1999;44:53-60.
33. Bresnick GH, Palta M. Oscillatory potential amplitudes: relation to severity of diabetic retinopathy. Arch Ophthalmol. 1987;105:929-933.
34. Sitges M, Nekrassov V, Guarneros A. Simultaneous action of MK- 801 (dizclopine) on dopamine, glutamate, aspartate and GABA release from striatum isolated nerve endings. Brain Res. 2000;854: 48-56.
35. Duarte AIS, Seica MS, Oliveira R, Catarina R. Oxidative stress affects synaptosomal _-aminobutyric acid and glutamate transport in diabetic rats: the role of insulin. Diabetes. 2004;53:2110-2116.
36. Zhu B, Wang W, Gu Q, Xu X. Erythropoietin protects retinal neurons and glial cells in early-stage streptozotocin-induced diabetic rats. Exp Eye Res. 2008;86:375-382.
37. Aizu YO, Hu K, Nakagawa JH. Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin- diabetic rats. Neuropathology. 2002;22:161-170.
38. Malendowicz LKN, Nussdorfer G, Nowak GG, Zyterska KW, Ziolkowska A. Prolonged exendin-4 administration stimulates pituitary- adrenocortical axis of normal and streptozotocin-induced diabetic rats. Int J Mol Med. 2003;12:593-596.
39. Perry T, Haughey NJ, Mattson MP, Egan JM, Greig NH. Protection and reversal of excitotoxic neuronal damage by glucagonlike peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002;302: 881-888.
40. Perry T, Greig NH. The glucagon-like peptides: a new genre in therapeutic targets for intervention in Alzheimer's disease. J Alzheimers Dis. 2002;4:487-496.
41. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflamm. 2008;5:19.
42. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623-634.
43. Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA. Elevated glutamate in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
44. Brooks DE, Garcia GA, Dreyer EB, Zurakowski D, Franco-Bourland RE. Vitreous body glutamate concentrations in dogs with glaucoma. Am J Vet Res. 1997;58:864-867.
45. Dkhissi OCE, Wasowicz M. Retinal TUNEL-positive cells and high glutamate levels in vitreous humor of mutant quail with a glaucoma- like disorder. Invest Ophthalmol Vis Sci. 1999;40:990-994.
46. Attwell DBB, Szatkowski M. Nonvesicular release of neurotransmitter. Neuron. 1993;11:401-407.
47. Storck T, Schulte S, Hofmann K, Stoffel W. Structure, expression, and functional analysis of a Na(_)-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci U S A. 1992;89: 10955-10999.
48. Pines GDN, Bjoras M. Cloning and expression of a rat brain Lglutamate transporter. Nature. 1992;360:464-467.
49. Kanai YHM. Primary structure and functional characterization of a high affinity glutamate transporter. Nature. 1992;360:467-471.
50. Arriza JL, Eliasof S, Kavanaugh MP, Amara SG. Excitatory amino acid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci U S A. 1997;94:4155-4160.
51. Fairman WA, Vandenberg RJ, Arriza JL, Kavanaugh MP, Amara SG. An excitatory amino-acid transporter with properties of a ligandgated chloride channel. Nature. 1995;375:599-603.
52. Rauen T, Taylor WR, Kuhlbrodt K, Wiessner M. High-affinity glutamate transporters in the rat retina: a major role of the glial glutamate transporter GLAST-1 in transmitter clearance. Cell Tissue Res. 1998;291:19-31.
53. Shelton MD, Kern TS, Mieyal JJ. Glutaredoxin regulates nuclear factor _B and intercellular adhesion molecule in Muller cells: model of diabetic retinopathy. J Biol Chem. 2007;282:12467-12474.